EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies

Arthi Palani iD, Sagar Patel, Shriya Patel, Shivani Srivastava, Jay Patel, Salman Salehin, Yochai Birnbaum, Joseph Allencherril

Cardiovascular Drugs and Therapy · 2026

DOI: 10.1007/s10557-025-07744-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, 2026. Verfasst von Arthi Palani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA. aap238@njms.rutgers.edu. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Insulin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review This review will summarize the most contemporary trials for glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and present guidance on management and recommendations on adjunctive tapering of insulin in patients with insulin-dependent diabetes mellitus, which we term “de-insulinization.” Recent Findings GLP1-RA and SGLT2-i are the principal classes of diabetes medications evidencing cardiovascular benefit. However, there is limited consensus on how to effectively prescribe and maintain these medications for patients on other glucose-lowering therapy, especially insulin. Summary Patients with type 2 diabetes and cardiovascular disease should be started on either a GLP-1RA, SGLT-i, or both in high-risk cases, while simultaneously tapering any prescribed insulin regimen. Initial selection and transition of therapy should be approached individually and systematically, with prioritization of patients with other comorbidities such as coronary artery disease, chronic kidney disease, and other diabetes complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsInsulinHypoglycemic AgentsBlood GlucoseIncretinsHumansCardiovascular DiseasesTreatment Outcome

Stichwörter der Autor:innen

Cardiovascular diseaseDiabetesGLP-1RAHeart failureInsulin de-escalationOutcomesSGLT2-i

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsInsulinHypoglycemic AgentsBlood GlucoseIncretins

Autor:innen und Institutionen

  • Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA. aap238@njms.rutgers.edu.
  • Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
  • Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
  • Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.

ORCID-Profile: Arthi Palani

Zitieren

APA

Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2026). GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-025-07744-8

Vancouver

Palani A, Patel S, Patel S, Srivastava S, Patel J, Salehin S, et al. GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies. Cardiovascular Drugs and Therapy. 2026. doi:10.1007/s10557-025-07744-8

BibTeX
@article{Palani2026,
  author = {Palani, Arthi and Patel, Sagar and Patel, Shriya and Srivastava, Shivani and Patel, Jay and Salehin, Salman and Birnbaum, Yochai and Allencherril, Joseph},
  title = {GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  doi = {10.1007/s10557-025-07744-8}
}
Kostenlos starten →